X0306 4 2018-10-23 0 0001664106 LogicBio Therapeutics, Inc. LOGC 0001752486 Ioannidou Sofia C/O LOGICBIO THERAPEUTICS, INC. 610 MAIN ST., 3RD FLOOR CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2018-10-23 4 C 0 1367413 A 1367413 I See Footnote Common Stock 2018-10-23 4 P 0 420000 10.00 A 1787413 I See Footnote Series B Convertible Preferred Stock 2018-10-23 4 C 0 2611665 0.00 D Common Stock 1367413 0 I See Footnote Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock. The Reporting Person is a director of Andera Partners, the company managing BioDiscovery 5. BioDiscovery 5 is the direct beneficial owner of these securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest. /s/ Matthias Jaffe, as Attorney-in-Fact 2018-10-25